Over the years, I have written extensively about ELLEX and its innovative ophthalmic lasers. However, in November 2007, just prior to that year’s AAO meeting, the company put out a news release about a new laser that had the potential to alleviate the early stages of age-related macular degeneration. The laser-based therapy was called ELLEX’s 2RT (Retinal Regeneration Therapy).

The theory behind the therapy was based on research conducted by Professor John Marshall at St. Thomas’ Hospital of London, and his colleague Dr. Ali Hussain. They found, after experimentation, that a Q-switched doubled YAG, (532 nm) operated at precise 3 ns pulses, could be used to trigger a renewal process of the retinal pigment epithelial cells (a sort of biostimulation) without damaging the overlying retina. This causes the RPE to migrate and release metalloproteinases, enzymes which act to clean up Bruchs membrane. The scientists were able to demonstrate and measure Bruch’s abilitly to transport water and chemicals and thus rejuvenate the retina.

For the rest of the story, please my complete writeup in my online Journal at:

http://irvaronsjournal.blogspot.com/2007/11/ellex-2rt-retina-regeneration-therapy.html ^[1]

Please submit any comments to this article below ^[2].

(picture of retina showing RPE layer.)